



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

July 30, 2013 6:00 – 8:30 p.m.

- 1. Executive Session** **6:00 - 6:30**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
 - Updates
 - Universal PA Forms

- 4. Medical Director Update** **6:45 - 6:45**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:45 - 7:00**
 - Pediatric Antipsychotic Medications
 - Second Reconsiderations by Medical Director/Substance Abuse Unit

- 6. RetroDUR/DUR** **7:00 – 7:15**
 - Buprenorphine with concomitant opiates, opiate combinations or tramadol

- 7. Clinical Update: Drug Reviews** **7:15 – 8:00**
(Public comment prior to Board action)

Abbreviated New Drug Reviews

- Giazol[®] (balsalazide disodium) Oral Tablet
- Ilevro[®] (nepafenac 0.3%) Ophthalmic Suspension
- Onmel[®] (itraconazole) 200 mg Oral Tablet
- Oxtellar XR[®] (oxcarbazepine) ER Oral Tablet
- Quillivant XR[®] (methylphenidate) ER Oral Suspension
- TOBI Podhaler[®] (tobramycin) Capsules for Inhalation
- Uceris[®] (budesonide) ER Oral Tablets

Full New Drug Reviews

- Eliquis[®] (apixaban) Oral Tablet
- Fulyzaq[®] (crofelemer) Delayed Release Oral Tablet
- Nesina[®], Oseni[®] & Kazano[®] (alogliptin, alogliptin/pioglitazone & alogliptin/metformin) Oral Tablets
- Tecfidera[®] (dimethyl fumarate) Oral Capsule
- Xelanz[®] (tofacitinib) Oral Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **8:00 – 8:15**
(Public comment prior to Board action)
Class review documents available on DVHA web site 07/30/2013 @ 12 Noon
- Immunomodulators
 - Multiple Sclerosis Agents
 - Oral Anticoagulants
- 9. New Managed Therapeutic Drug Classes** **8:15 – 8:15**
(Public comment prior to Board action)
- None
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:15 – 8:25**
(Public comment prior to Board action)
- Crinone[®]
 - Makena[®]
 - Second Generation Cephalosporins
 - Short Acting Beta Agonist Inhalers (for January 1st 2014 implementation)
- 11. General Announcements** **8:25– 8:30**
Selected FDA Safety Alerts
- Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
 - Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection
- 12. Adjourn** **8:30**